Ekso Bionics Holdings, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

7. Accrued Liabilities

Accrued liabilities as of March 31, 2026 and December 31, 2025 consisted of the following:

	*March 31, 2026*		*December 31, 2025*
Salaries, benefits and related expenses	$	1,157	$	1,198
Device warranty		309		363
Other		257		218
Total	$	1,723	$	1,779

Warranty

Sales of devices generally include an initial warranty for parts and services for one to two years in the Americas, two years in EMEA, and one to three years in APAC. Warranty costs are reflected in the condensed consolidated statements of operations and comprehensive loss as a component of costs of revenue. The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three months ended March 31, 2026 is as follows:

	*Three Months Ended*
	*March 31, 2026*
Balance as of beginning of period	$	452
Additions for estimated future expense		54
Incurred costs		(125	)
Balance at end of the period	$	381

	*Balance as of March 31, 2026*
Current portion	$	309
Long-term portion		72
Total	$	381